Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.6K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.6K
Preclinical Development: Overview01:28

Preclinical Development: Overview

6.3K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.3K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.6K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.6K
Pharmacodynamic Models: Linear Concentration–Effect Model01:15

Pharmacodynamic Models: Linear Concentration–Effect Model

51
The linear concentration–effect model, underpinned by the principle that pharmacological effect (E) is directly proportional to plasma drug concentration (C), emerges as a pivotal simplification of the Emax model for conditions where C is significantly less than EC50. This model portrays a linear trajectory of the concentration–effect relationship when drug levels are markedly below the EC50 threshold.Despite its inherent assumption of continuous effect augmentation with increasing...
51
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

68
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
68
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

895
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
895

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploratory analysis of PTEN deficiency by immunohistochemistry from the Phase III CAPItello-291 trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Evaluation of metformin for epilepsy prevention or seizure control in people without evidence of diabetes: retrospective cohort study.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Seizure prophylaxis in glioma surgery (SPRING): A multi-center, unblinded, randomized trial.

Neuro-oncology practice·2026
Same author

HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

British journal of clinical pharmacology·2026
Same author

Development and Validation of Pharmacology Concept Inventory for Concept-Based Learning: Leveraging Theory, Expert Insights, and Student Perspectives.

Pharmacology research & perspectives·2026
Same author

Seizure prophylaxis in glioma surgery: a synopsis from the SPRING RCT.

Health technology assessment (Winchester, England)·2026

Related Experiment Video

Updated: Mar 15, 2026

Preparation of Acute Human Hippocampal Slices for Electrophysiological Recordings
07:31

Preparation of Acute Human Hippocampal Slices for Electrophysiological Recordings

Published on: May 7, 2020

8.1K

Clinical Drug Development in Epilepsy Revisited: A Proposal for a New Paradigm Streamlined Using Extrapolation.

Ian Wadsworth1, Thomas Jaki1, Graeme J Sills2

  • 1MRC North-West Hub for Trials Methodology Research, Department of Mathematics and Statistics, Fylde College, Lancaster University, Lancaster, LA1 4YF, UK.

CNS Drugs
|September 15, 2016
PubMed
Summary

Extrapolating adult clinical trial data can streamline pediatric drug development for epilepsies. This approach aims to reduce trial sizes and costs, enabling earlier access to new treatments for children.

More Related Videos

A Model of Epileptogenesis in Rhinal Cortex-Hippocampus Organotypic Slice Cultures
10:05

A Model of Epileptogenesis in Rhinal Cortex-Hippocampus Organotypic Slice Cultures

Published on: March 18, 2021

7.7K
Generation and On-Demand Initiation of Acute Ictal Activity in Rodent and Human Tissue
06:45

Generation and On-Demand Initiation of Acute Ictal Activity in Rodent and Human Tissue

Published on: January 19, 2019

9.5K

Related Experiment Videos

Last Updated: Mar 15, 2026

Preparation of Acute Human Hippocampal Slices for Electrophysiological Recordings
07:31

Preparation of Acute Human Hippocampal Slices for Electrophysiological Recordings

Published on: May 7, 2020

8.1K
A Model of Epileptogenesis in Rhinal Cortex-Hippocampus Organotypic Slice Cultures
10:05

A Model of Epileptogenesis in Rhinal Cortex-Hippocampus Organotypic Slice Cultures

Published on: March 18, 2021

7.7K
Generation and On-Demand Initiation of Acute Ictal Activity in Rodent and Human Tissue
06:45

Generation and On-Demand Initiation of Acute Ictal Activity in Rodent and Human Tissue

Published on: January 19, 2019

9.5K

Area of Science:

  • Clinical pharmacology
  • Pediatric neurology
  • Drug development

Background:

  • Extrapolation of adult data can reduce pediatric clinical trial requirements.
  • Current methods for pediatric epilepsy drug development may be inefficient.
  • Paediatric epilepsies require tailored therapeutic strategies.

Purpose of the Study:

  • To propose a new paradigm for developing drugs for pediatric focal epilepsies.
  • To outline the role of data extrapolation in pediatric drug licensing.
  • To identify benefits for patients, clinicians, and sponsors.

Main Methods:

  • Consensus expert opinion was used to formulate the proposal.
  • Phase I trials in adults.
  • Simultaneous Phase II and III trials in adults and children over 2 years old.
  • Phase IV data collection for neurodevelopmental safety in children.

Main Results:

  • A single trial program can support licensing for adjunctive therapy or monotherapy.
  • Provisional licensing for children contingent on Phase IV safety data.
  • The proposed paradigm aims to reduce costs and expedite access to novel treatments.

Conclusions:

  • The proposed paradigm offers a more efficient pathway for pediatric epilepsy drug development.
  • This approach benefits all stakeholders by reducing costs and improving treatment access.
  • Further consultation with patients, guardians, and regulatory bodies is necessary.